Novo Nordisk’s Critical Crossroads: A December Reckoning

The investment case for Danish pharmaceutical giant Novo Nordisk appears to be in tatters as 2025 unfolds, with its equity value having collapsed by more than half since January. Facing brutal price competition and legal setbacks, anxious shareholders are now focusing on a single date in early December. The central question is whether a potential breakthrough in Alzheimer’s research can reverse the company’s fortunes or if a complete collapse is imminent.

The slight share price recovery observed last Friday does little to mask the stock’s desperate need for positive catalysts. All eyes are turning toward approximately December 3, when Novo Nordisk will unveil Phase 3 (EVOKE) trial data for oral Read more...